Drug Discovery Statistics 2024 – Everything You Need to Know

by

Are you looking to add Drug Discovery to your arsenal of tools? Maybe for your business or personal use only, whatever it is – it’s always a good idea to know more about the most important Drug Discovery statistics of 2024.

My team and I scanned the entire web and collected all the most useful Drug Discovery stats on this page. You don’t need to check any other resource on the web for any Drug Discovery statistics. All are here only 🙂

How much of an impact will Drug Discovery have on your day-to-day? or the day-to-day of your business? Should you invest in Drug Discovery? We will answer all your Drug Discovery related questions here.

Please read the page carefully and don’t miss any word. 🙂

Best Drug Discovery Statistics

☰ Use “CTRL+F” to quickly find statistics. There are total 98 Drug Discovery Statistics on this page 🙂

Drug Discovery Benefits Statistics

  • When combined with the lower tax rate, that change will reduce the first year tax benefits for R&D spending on orphan drugs by about 40 percent. [0]

Drug Discovery Market Statistics

  • Biologics also accounted for a large proportion in neoplasms (40.8%). [1]
  • A previous survey targeting public‐sector research institutions reported the modalities of drug products brought to market as follows 60.8% small molecules; 33.3% biologics; 5.3% diagnostic drugs; and 1% over‐the‐counter drugs. [1]
  • The expected cost to develop a new drug—including capital costs and expenditures on drugs that fail to reach the market—has been estimated to range from less than $1 billion to more than $2 billion. [0]
  • CBO estimated that under the bill, approximately 8 fewer drugs would be introduced to the U.S. market over the 2020–2029 period and about 30 fewer drugs over the subsequent 10 years.1. [0]

Drug Discovery Software Statistics

  • By comparison, other research intensive industries, like software and semiconductors, averaged about 15 percent. [0]
  • 3 percent.5 R&D intensity in the software and semiconductor industries, which are generally comparable to the drug industry in their reliance on research and development, has remained below 18 percent. [0]
  • Finally, the drug was docked to the predicted drug binding site using the protein–ligand docking software eHiTs. [2]
  • Furthermore, we docked the drug molecules to the predicted drug binding site using the software eHiTs. [2]

Drug Discovery Latest Statistics

  • The observed success rates of academic drug discovery and development were 75% at phase I, 50% at phase II, 59% at phase III, and 88% at the new drug application/biologics license application phase. [1]
  • I clinical trials remains at ~10%. [1]
  • The universities were selected according to their rankings in “The 2014–2015 Times Higher Education World University Rankings’ clinical, preclinical, and health.”. [1]
  • 3The decision on whether a project was suspended or not was made according to the database. [1]
  • Diseases were classified according to the International Statistical Classification of Diseases and Related Health Problems 10th Revision. [1]
  • (30%)52% 10 (34%)80% 8 (50%)88% 7 (. [1]
  • (13%)100% 2 (14%)8%No collaboration with the industry246 (73%)35% 49 (60%)76% 11 (. [1]
  • (27%)36% 32 (40%)84% 21 (66%)48% 5 (71%)29% 2. [1]
  • (100%)12%Diseases of the nervous system65 (8%)23% 10 (5%)60% 3 (4%)33% 1. [1]
  • (6%)100% 1 (7%)20%Diseases of the circulatory system46. [1]
  • (6%)28% 12 (6%)67% 4 (5%)25% 1 (3%)100% 1 (6%)0% 0. [1]
  • (6%)38% 12 (6%)75% 5 (7%)80% 2. [1]
  • (7%)100% 2 (13%)100% 2 (14%)60%Endocrine, nutritional, and metabolic diseases43 (5%)44% 16 (9%)69% 6 (8%)83% 3. [1]
  • (19%)100% 3 (21%)11%Diagnostic drug30 (4%)70% 13 (7%)85% 6 (8%)100% 5 (17%)80% 4. [1]
  • (1%)44% 3 (2%)33% 1 (1%)100% 1 (3%)0% 0. [1]
  • (0%)NRICD‐10, International Statistical Classification of Diseases and Related Health Problems 10th revision; NDA/BLA, new drug application and biologics license application; NR, not reportable. [1]
  • 16Success rates and collaboration with private companiesThe success rate of each drug discovery stage in academia was 31.8% for preclinical, 75.1% for phase I, 50.0% for phase II, 58.6% for phase III, and 87.5% for NDA and BLA. [1]
  • The LOA from phase I to approval was 19.3% .Phase success and likelihood of approvals. [1]
  • The respective success rates of collaborating projects compared with noncollaborating projects was 78.2% vs. 71.4% in phase I, 54.4% vs. 36.8% in phase II, 63.0% vs. 0% in phase III, and 87.5% vs. 0% at NDA/BLA. [1]
  • The number of projects involving the nervous and circulatory systems were relatively small, and phase II success rates seemed lower in these two domains (i.e., 33% for nervous system projects and 25% for circulatory system projects). [1]
  • ModalitiesThere were 56% small molecules, 39% biologics, 4% diagnostics, and 1% other modalities .5). [1]
  • The proportion of biologics was particularly high in projects related to diseases of the blood and blood‐forming organs as well as for certain disorders involving the immune mechanism (77.3%). [1]
  • The percentage and total number of patents awarded to academic entities have increased in tandem.19. [1]
  • A previous report estimated that between 1996 and 2007, university‐based research‐licensing agreements rose in contribution to the gross domestic product, increasing from US $47 billion to $187 billion. [1]
  • For example, although the success rates reported by the Biotechnology Innovation Organization were 63% for phase I and 31% for phase II,Our results suggest that this issue is also evident in academic drug discovery. [1]
  • For example, although the success rates reported by the Biotechnology Innovation Organization were 63% for phase I and 31% for phase II,22our results for academic success rates indicated 75% for phase I and 50% for phase II. [1]
  • The success rates reported by BIO were 58% for phase III and 85% for NDA/BLA,our results for academic success rates indicated 75% for phase I and 50% for phase II. [1]
  • The success rates reported by BIO were 58% for phase III and 85% for NDA/BLA,4whereas. [1]
  • our results for success rates in academia were 59% for phase III and 88% for NDA/BLA. [1]
  • This may lead to academia’s overall dominance regarding LOAs (i.e., 19.3% vs. the industry’s 9.6%). [1]
  • This is probably due to a large proportion of phases II and III biologics projects being targeted at neoplasms (phase II 67% and phase III 63%). [1]
  • About 40% of the academic drug discovery projects involved biologics, which indicates that academia takes on leading‐edge and challenging projects in terms of both drug modality and disease domain. [1]
  • (1%)44% 3 (2%)33% 1 (1%)100% 1 (3%)0% 0 (0%)NR0. [1]
  • The success rate of each drug discovery stage in academia was 31.8% for preclinical, 75.1% for phase I, 50.0% for phase II, 58.6% for phase III, and 87.5% for NDA and BLA. [1]
  • The LOA from phase I to approval was 19.3%. [1]
  • Academic‐industrial collaboration seemed to have some positive impact on academic drug discovery; the nonclinical success rate was 36.7% for collaborating projects and 29.5% for noncollaborating projects . [1]
  • There were 56% small molecules, 39% biologics, 4% diagnostics, and 1% other modalities .5). [1]
  • The proportion of biologics was also high in diseases of the eyes and adnexa (47.1%), diseases of the respiratory system (43.5%), and diseases of the musculoskeletal system and connective tissue (50.0%). [1]
  • According to a report by the Pharmaceutical Research and Manufacturers of America , the average cost associated with developing a drug to the approval stage has increased since the 2000s, reaching US $2.6 billion in the first half of the 2010s. [1]
  • The pharmaceutical industry is facing a crisis is R&D. About 50% of late stage clinical trials fail due to ineffective drug targets, resulting in only 15% of drugs advancing from Phase 2 to approval. [3]
  • It is estimated that by 2024 the top worldwide pharmaceutical companies based on research and development spending will be Johnson & Johnson, Roche and Merck &. [4]
  • Available to download in PNG, PDF, XLS format 33% off until Jun 30th. [4]
  • Indeed, about 20% of startups have received 80% of funds. [5]
  • Between 2010 and 2019, the number of new drugs approved for sale increased by 60 percent compared with the previous decade, with a peak of 59 new drugs approved in 2018. [0]
  • On average, the Food and Drug Administration approved 38 new drugs per year from 2010 through 2019 , which is 60 percent more than the yearly average over the previous decade. [0]
  • Only about 12 percent of drugs entering clinical trials are ultimately approved for introduction by the FDA. [0]
  • In particular, spending on drug R&D increased by nearly 50 percent between 2015 and 2019. [0]
  • The 30 largest companies have developed 53 percent of drugs approved since 2009, and in 2014, the 25 largest drug companies received more than 70 percent of industry revenues. [0]
  • NSF’s estimates of R&D spending since 2008 suggest that PhRMA members’ worldwide R&D spending constitutes about 75 percent to 85 percent of the industry total, depending on the year. [0]
  • In the early 2000s, when drug industry revenues were rising sharply, the industry’s R&D intensity—that is, its R&D spending as a share of net revenues—averaged about 13 percent each year. [0]
  • Over the decade from 2005 to 2014, the industry’s R&D intensity averaged 18 percent to 20 percent each year. [0]
  • That ratio has been trending upward since 2012, and it exceeded 25 percent in 2018 and 2019, the highest R&D intensities recorded by the pharmaceutical industry as a whole since at least 2000. [0]
  • Data are limited for earlier years, but among PhRMA member companies, annual R&D intensities averaged 18 percent from 1980 through 2010 and never exceeded 22 percent.4. [0]
  • Since then, R&D intensity has increased among PhRMA firms just as it has for the industry as a whole, reaching 25 percent in 2017 before decreasing slightly in 2018. [0]
  • By comparison, average R&D intensity across all industries typically ranges between 2 percent and. [0]
  • That is about a 60 percent increase compared with the previous decade. [0]
  • That is because the new drugs successfully treat about 95 percent of patients with chronic hepatitis C infection.8. [0]
  • According to the World Health Organization, more than 200 candidate COVID 19 vaccines were in development in February 2021.41. [0]
  • According to one study, the preclinical phase takes an average of about 31 months, followed by around 95 months, on average, for clinical trials—or about 10.5 years from start to finish.16. [0]
  • R&D costs have increased by about 8.5 percent per year over roughly the past decade. [0]
  • The 2016 study found that fewer than 12 percent of the drugs entering phase. [0]
  • Taken together, federal and state expenditures on prescription drugs accounted for about 40 percent of total U.S. retail expenditures on prescription drugs in 2019.Changes to those programs would influence R&D spending. [0]
  • Between 2003 and 2010, the number of drugs entering phase I clinical trials increased by roughly 50 percent in therapeutic classes with relatively high sales to Medicare enrollees. [0]
  • Investment in R&D is encouraged by the reduction in the top corporate tax rate from 35 percent to 21 percent because earnings on new drugs would be taxed at a lower rate. [0]
  • The 2017 tax act also reduced the tax credit created by the Orphan Drug Act from 50 percent to 25 percent of the cost of clinical trials.48. [0]
  • Several studies have found that a real 10 percent decrease in the growth of drug prices would be associated with about a 6 percent decrease in pharmaceutical R&D spending as a share of net revenues.66Clinical Trials. [0]
  • 24, no. 8 , www.centerwatch.com/articles/13284%20.19. [0]
  • The values reported here all use a 7 percent cost of capital, as each study includes calculations that use that rate. [0]
  • [0]
  • The values reported in the 2016 DiMasi study, in millions of 2013 dollars and using their central discount rate value of 10.5 percent, are $2,558, $1,098, and $1,460, respectively.25. [0]
  • See Olivier J. Wouters, Martin McKee, and Jeroen Luyten, “Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009–2018,” Journal of the American Medical Association, vol. [0]
  • The study’s central published values differ from those reported above they are expressed in 2018 dollars and use a 10.5 percent cost of capital. [0]
  • The authors also estimated R&D costs using a 7 percent discount rate. [0]
  • Pharmaceutical companies have devoted a growing share of their net revenues to R&D activities, averaging about 19 percent over the past two decades. [0]
  • According to the World Health Organization, more than 200 candidate COVID 19 vaccines were in development in February 2021.4. [0]
  • Several studies have found that a real 10 percent decrease in the growth of drug prices would be associated with about a 6 percent decrease in pharmaceutical R&D spending as a share of net revenues.66 Clinical Trials. [0]
  • 24, no. 8 , www.centerwatch.com/articles/13284%20. [0]
  • The values reported in the 2016 DiMasi study, in millions of 2013 dollars and using their central discount rate value of 10.5 percent, are $2,558, $1,098, and $1,460, respectively. [0]
  • For an analysis of likely effects of such a policy change on individuals’ decisions about health insurance and consumption of health care services in general, see Congressional Budget Office, Options for Reducing the Deficit 2019 to 2028 ,. [0]
  • Percentage of adolescents reporting drug use decreased significantly in 2021 as the COVID 19 pandemic enduredView InfographicMonitoring the. [6]
  • There were 91,799 drug involved overdose deaths reported in the U.S. in 2020 ; 69% of cases occurred among males. [7]
  • More than 70% of deaths occurred among males. [7]
  • More than 68% of overdose deaths involving heroin also involved synthetic opioids other than methadone. [7]
  • The EVD is determined by two parameters Îź and σ, which are estimated from linear regression of the rearrangement of Equations 4 and 5 as S2 = Îź + σ)). [2]
  • The sequence identity between each pair of chains was below 30%. [2]
  • Previously the statistical significance of the ligandbinding site similarity was estimated based on a non parametric statistical method. [2]
  • As shown in Figure 4, the true positive rate increases around 2% and 1% for BLOSUM45 and McLachlan substitution matrix, respectively, when the false positive rate is 1%. [2]
  • Percentge of flse positive rte versus true positive rte for the originl SOIPPA lgorithm nd the improved SMAP implementtion using. [2]
  • As shown in Table 2, most of the predicted binding sites were similar to a known drug binding site with high statistical significance. [2]

I know you want to use Drug Discovery Software, thus we made this list of best Drug Discovery Software. We also wrote about how to learn Drug Discovery Software and how to install Drug Discovery Software. Recently we wrote how to uninstall Drug Discovery Software for newbie users. Don’t forgot to check latest Drug Discovery statistics of 2024.

Reference

  1. cbo – https://www.cbo.gov/publication/57126.
  2. nih – https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226120/.
  3. oup – https://academic.oup.com/bioinformatics/article/25/12/i305/191336.
  4. statnews – https://www.statnews.com/2019/11/01/ai-revolutionize-drug-discovery-experts-involved/.
  5. statista – https://www.statista.com/statistics/765535/drug-discovery-market-worldwide-by-segment-globally/.
  6. benchsci – https://blog.benchsci.com/artificial-intelligence-in-drug-discovery-trends-and-statistics.
  7. nih – https://nida.nih.gov/drug-topics/trends-statistics/monitoring-future.
  8. nih – https://nida.nih.gov/drug-topics/trends-statistics/overdose-death-rates.

How Useful is Drug Discovery

One of the primary reasons why drug discovery is so valuable is its ability to address unmet medical needs. There are countless diseases and medical conditions for which there are currently no effective treatments available. Drug discovery works to fill these gaps by identifying new therapeutic targets, understanding disease mechanisms, and developing new drugs to target these areas. This gives hope to patients suffering from rare or difficult-to-treat conditions, offering them a chance for a better future.

Additionally, drug discovery plays a vital role in combating emerging health threats, such as antibiotic resistance, new strains of infectious diseases, and chronic conditions like cancer and diabetes. By continuously researching and developing new drugs, scientists can stay ahead of these evolving challenges and provide patients with the most effective and up-to-date treatments available. This proactive approach to healthcare is crucial in protecting public health and addressing global health crises.

Furthermore, drug discovery drives innovation in the pharmaceutical industry, leading to the creation of new technologies, methodologies, and treatment protocols. As researchers uncover novel drug targets, develop cutting-edge therapies, and engage in collaborative partnerships, they push the boundaries of medical science and advance our understanding of disease processes. This creativity and ingenuity drive progress in healthcare and inspire future generations of scientists to continue exploring new frontiers in drug discovery.

Moreover, drug discovery fosters economic growth and job creation, as pharmaceutical companies invest in research and development, clinical trials, and manufacturing processes. The pharmaceutical industry is a significant contributor to the economy, employing millions of people worldwide and generating billions of dollars in revenue. By supporting drug discovery efforts, governments, institutions, and private sector investors can stimulate economic development and promote scientific innovation in their countries.

On a more personal level, drug discovery offers hope and healing to individuals and their families who are facing serious illnesses and health challenges. Through the development of new medications, patients can experience improved health outcomes, increased longevity, and better quality of life. These advancements in medical science provide comfort and relief to those who are suffering and struggling with their conditions, offering them a sense of empowerment and confidence in their treatment options.

In conclusion, drug discovery is an invaluable tool in the fight against disease and in the quest for improved healthcare outcomes. Its impact is far-reaching, benefiting individuals, communities, and societies as a whole. By investing in drug discovery and supporting research efforts, we can continue to drive progress in medicine, elevate human health, and build a brighter future for generations to come.

In Conclusion

Be it Drug Discovery benefits statistics, Drug Discovery usage statistics, Drug Discovery productivity statistics, Drug Discovery adoption statistics, Drug Discovery roi statistics, Drug Discovery market statistics, statistics on use of Drug Discovery, Drug Discovery analytics statistics, statistics of companies that use Drug Discovery, statistics small businesses using Drug Discovery, top Drug Discovery systems usa statistics, Drug Discovery software market statistics, statistics dissatisfied with Drug Discovery, statistics of businesses using Drug Discovery, Drug Discovery key statistics, Drug Discovery systems statistics, nonprofit Drug Discovery statistics, Drug Discovery failure statistics, top Drug Discovery statistics, best Drug Discovery statistics, Drug Discovery statistics small business, Drug Discovery statistics 2024, Drug Discovery statistics 2021, Drug Discovery statistics 2024 you will find all from this page. 🙂

We tried our best to provide all the Drug Discovery statistics on this page. Please comment below and share your opinion if we missed any Drug Discovery statistics.

Leave a Comment